financetom
Business
financetom
/
Business
/
China says it opposes latest US tariff threat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
China says it opposes latest US tariff threat
Feb 27, 2025 9:53 PM

BEIJING (Reuters) - China on Friday said it opposed President Donald Trump's latest threat to slap an extra 10% duty on Chinese imports over deadly drug flows into the U.S., accusing the White House of "shifting the blame" and taking steps to destabilise global supply chains.

Trump said on Thursday his proposed 25% tariffs on Mexican and Canadian goods will take effect on Tuesday, along with an extra 10% duty on Chinese imports.

The fresh China tariffs, in addition to the 10% tariff levied on Feb 4, coincide with the start of China's annual parliamentary meetings on Wednesday, a set-piece political event where Beijing is expected to unveil its main economic priorities for 2025.

"We have repeatedly stated that unilateral tariffs violate World Trade Organization rules and undermine the multilateral trading system," a commerce ministry spokesperson said in a statement.

"China has one of the strictest and most thoroughly enforced anti-drug policies in the world," it said. "Now, (the U.S.) once again is threatening additional tariffs. This behaviour is nothing more than shifting the blame and shirking responsibility."

The announcement also leaves Beijing less than a week to publish countermeasures, as the Trump administration shows signs of a hardening stance towards its strategic rival despite backing down on the threat of 60% tariffs when Trump took office.

"China urges the U.S. not to repeat its mistakes and to return to the correct path of resolving disputes through equal dialogue as soon as possible," the statement said.

"If the U.S. insists on proceeding with this course of action, China will take all necessary countermeasures to safeguard its legitimate rights and interests."

(Reporting by Joe Cash; Editing by Shri Navaratnam and Lincoln Feast.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--GXO Logistics Shares Rise Pre-Bell After Bloomberg Reports Company Exploring Sale
--GXO Logistics Shares Rise Pre-Bell After Bloomberg Reports Company Exploring Sale
Oct 10, 2024
07:58 AM EDT, 10/10/2024 (MT Newswires) -- Price: 56.06, Change: +5.16, Percent Change: +10.14 ...
Immatics Launches $150 Million Public Offering of Ordinary Shares
Immatics Launches $150 Million Public Offering of Ordinary Shares
Oct 10, 2024
07:58 AM EDT, 10/10/2024 (MT Newswires) -- Immatics ( IMTX ) said Thursday that it has launched a $150 million underwritten public offering of its ordinary shares. The company said there is no guarantee as to when or if the offering will be completed, or as to the actual size and terms of the offering, as these are contingent on...
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
Oct 10, 2024
NEW YORK, Oct 10 (Reuters) - U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent ( CTLT ), saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs. Novo Holdings, the investment firm that has a...
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell
Oct 10, 2024
07:56 AM EDT, 10/10/2024 (MT Newswires) -- Tempest Therapeutics ( TPST ) said Thursday it is working with Roche to advance amezalpat into a phase 3 trial in combination with atezolizumab and bavacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma. As part of the agreement, Roche will provide atezolizumab worldwide, while Tempest will sponsor and lead the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved